Weaver Capital Management LLC Sells 1,548 Shares of Becton, Dickinson and Company (NYSE:BDX)

Weaver Capital Management LLC cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 29.6% during the 3rd quarter, Holdings Channel reports. The firm owned 3,688 shares of the medical instruments supplier’s stock after selling 1,548 shares during the period. Weaver Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $889,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of BDX. Livelsberger Financial Advisory purchased a new position in shares of Becton, Dickinson and Company during the third quarter valued at approximately $26,000. Sound Income Strategies LLC boosted its stake in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company during the second quarter valued at about $45,000. Abound Wealth Management raised its stake in Becton, Dickinson and Company by 96.0% in the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 96 shares in the last quarter. Finally, Tributary Capital Management LLC purchased a new stake in Becton, Dickinson and Company in the first quarter worth about $49,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.4 %

Shares of NYSE BDX opened at $239.66 on Wednesday. The firm’s 50 day moving average price is $237.20 and its 200-day moving average price is $235.12. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $262.23. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The company has a market cap of $69.26 billion, a PE ratio of 52.79, a P/E/G ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.96 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on BDX. Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI increased their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Raymond James lowered their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.